Who Pays To Johnson & Johnson?

Chain stores (Walgreens, CVS, Rite-Aid, Walmart), clinics, long term care facilities, health
maintenance organizations, federal facilities, non-federal institutions, mail order pharmacies, and
retail stores.

What Are The Alternatives To Johnson & Johnson?

Within pharmaceuticals, other alternatives are Bristol-Myers Squibb, Roche, Pfizer, Merck, Abbvie,
GlaxoSmithKline, and Teva, among others.

Outside of pharmaceuticals, other alternatives are acupuncture, aromatherapy, ayurvedic medicine,

chiropractic care, homeopathy, and nutritional counseling, among others.

In Medical Devices, Johnson & Johnson competes with Boston Scientific, Medtronic, Abbott Labs,
and Intuitive Surgical.

Johnson & Johnson's Pharmaceuticals Business To Account For 53% of The

Company's Total Revenue In 2020, And It Will Also Grow At A Much Faster Pace
Compared To The Company's Other Segments

Pharmaceuticals expected to be the single-biggest revenue driver in 2020 with $43.7

billion in revenues (53% of Total Revenues), which is 1.8x the size of its Medical
Devices business, and 3.1x the size of its Consumer Healthcare Business.

Pharmaceuticals will also be the fastest growing segment, adding $7.4 billion over
2017-20.

Medical Devices will likely see a decline $2.8 billion, and Consumer Healthcare will
add $0.4 billion.

What Is Big?

1. Pharmaceuticals: $43.7 B (52%)

2. Medical Devices: $23.8 B (31%)
3. Consumer Healthcare: $14.0 B (17%)
-----------------------------------------------------------
Total Revenue In 2020E: $81.6 B

What Has Changed?

From 2017 To 2020E

Pharmaceuticals: $7.4 B
+ Medical Devices: $(2.8) B
+ Consumer Healthcare: $0.4 B
-----------------------------------------------------------
Total Change 2017-2020E: $5.0 B
+ J&J's Revenue In 2017: $76.5 B
= Total Revenue In 2020E: $81.6 B

Pfizer swot analysis:

Strength:

The business or selling of drug companies is related to the reputation it earns. Pfizer was ranked in
the second-most familiar among 14 drug companies. It was analyzed by the Reputation Institute.

staying for a long time in the market (founded in 1849), it gathered a strong experience base about
the business.

Weaknesses:

Allocate lower expenses for R&D department comparing to its competitors. It can make Pfizer
weaker as the R&D is the heart of a pharmaceutical company.

when working with other companies to achieve a market advantage, it may achieve a bad reputation
as well. Because there maybe are some external factors on which the company does not have direct
controls.

Opportunities:

people are becoming more caring for their health. It will increase the sales of healthcare products.

it will create scope to make more business in developing countries where the main competitors are
local pharmaceutical companies.

Threat:

War for prize between competitors may result in price reducing pressure. It may reduce the profit
margin in future.
There is some intensive government regulation in the sector of healthcare products. So, Pfizer
maybe is developing a new product but, a government regulatory board may not agree to accept
that product in their country.